A comprehensive study of Regulatory compliance for Biosimilars in US, EU and India

Journal Title: International Journal of Drug Regulatory Affairs - Year 2019, Vol 7, Issue 2

Abstract

The biopharmaceutical industry has gained significant interest in the last decade as the numbers of blockbuster biologic products are losing their patent rights. The regulatory authority is also providing marketing approval for Biosimilar products. Biological medicines are biotechnology developed drugs having large molecule which is complex in nature and are very sensitive to manufacturing conditions and parameters. Even a minor change in manufacturing conditions alters the quality and safety aspects of end product owing to increased risk for immune response. Biopharmaceutical companies use information technology such as molecular modelling and statistical data for drug development. Biosimilar drugs have moderate marketing cost which is alluring and generally 40 to 50 % less to that of originator drug product. Biosimilars are also known as “follow on biologics” or “similar biologics”. The following points needs consideration such as global harmonization, extrapolation studies, interchangeability study, long term post marketing studies to gain physician confidence in biosimilars.

Authors and Affiliations

Anshul Bansal, Vikesh Kumar Shukla, Shikha Chauhan

Keywords

Related Articles

A PARADIGM SHIFT IN DRUG REGULATIONS IN TAIWAN

Across Asia, a convergence of economic trends, government policies and greater awareness among the general public of healthcare issues has created an environment that is poised for dramatic growth and change. Taiwan, for...

OVERVIEW OF DRUG REGULATORY AFFAIRS AND REGULATORY PROFESSION

Pharmaceutical drug regulatory affairs govern registration parameters of pharmaceutical products. It has a broad spectrum covering all aspects of documentation and marketing in legalized form. The pharmaceutical industry...

MEDICAL DEVICES AND THEIR APPROVAL PROCEDURE IN INDIA

Therapeutic treatment based on medical devices is providing technologically advanced solutions for the management of several diseases. Thereby continues to grow in market at tremendous rate. However, these treatments als...

INSIDE STORY FOR REVIEW OF AN ABBREVIATED NEW DRUG APPLICATION

ANDA constitutes an important submission for marketing authorization of generic drugs. The FDA has recently mandated an electronic submission in the form of eCTD for the same. ANDA application is quite complex with respe...

REGULATORY REQUIREMENTS & MARKETING AUTHORIZATION OF GENERIC DRUGS IN SINGAPORE & THAILAND

The availability of generic medication is an important issue in the ASEAN region. The regulatory requirements of various countries vary from each other. Therefore, it is challenge for the companies to get drug approved f...

Download PDF file
  • EP ID EP625608
  • DOI 10.22270/ijdra.v7i2.313
  • Views 118
  • Downloads 0

How To Cite

Anshul Bansal, Vikesh Kumar Shukla, Shikha Chauhan (2019). A comprehensive study of Regulatory compliance for Biosimilars in US, EU and India. International Journal of Drug Regulatory Affairs, 7(2), 17-34. https://europub.co.uk./articles/-A-625608